The primary purpose of the Animal Resources Core is to facilitate cancer relevant animal projects at the Sidney Kimmel Comprehensive Cancer Center (SKCCC). The Johns Hopkins Department of Research Animal Resources oversees all laboratory animal resources and services of The Johns Hopkins University (JHU), including the SKCCC Animal Resources Core. However, due to the unique programs and goals of the SKCCC Animal Resources Core, it is managed as a separate functional unit, under the direction of the Associate Provost for Research Animal Resources and the SKCCC, and is designed specifically to enable investigator- initiated cancer therapeutic investigations in animals. The SKCCC animal care program and facilities are reviewed alongside Research Animal Resources and are fully accredited by the Association for Assessment and Accreditation of Laboratory Animal Care International. The SKCCC Animal Resources Core is located in two buildings: 1) the ground level of the SKCCC Cancer Research Building I (CRBI), which contains 8,069 net ft2 of space, and 2) the basement level of the SKCCC Cancer Research Building II (CRBII) which contains 29,831 net ft2 of space. Services provided include animal procurement, daily care and oversight, microbiological and sentinel monitoring, veterinary and pathology services, training and assistance with animal handling and technical procedures, maintenance of genetically altered and immunodeficient rodent breeding colonies, cross-fostering of rodent pups, and management of special facilities for the use of BSL2 and BSL3 hazardous agents. The veterinary, microbiological monitoring and pathology services are performed by the Johns Hopkins Department of Research Animal Resources on a fee-for-service basis. Cynthia Zahnow, Ph.D., Core Director, is responsible for the overall management and direction of the SKCCC Animal Resources Core. Sherrie Hawkes is Supervisor of the Animal Resources Core and is responsible for the day-to-day direction and operation of the Core. SKCCC Managed Core Reporting Period: Jan. 1, 2015, to Dec. 31, 2015

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA006973-55
Application #
9519867
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
Project End
Budget Start
2018-05-01
Budget End
2019-04-30
Support Year
55
Fiscal Year
2018
Total Cost
Indirect Cost
Name
Johns Hopkins University
Department
Type
DUNS #
001910777
City
Baltimore
State
MD
Country
United States
Zip Code
21205
Antonarakis, Emmanuel S; Lu, Changxue; Luber, Brandon et al. (2018) Germline DNA-repair Gene Mutations and Outcomes in Men with Metastatic Castration-resistant Prostate Cancer Receiving First-line Abiraterone and Enzalutamide. Eur Urol 74:218-225
Zarif, Jelani C; Antonarakis, Emmanuel S (2018) Targeting ELK1: a wELKome addition to the prostate cancer armamentarium. AME Med J 3:
Martino, Thiago; Kudrolli, Tarana A; Kumar, Binod et al. (2018) The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress. Prostate 78:140-151
Isaacsson Velho, Pedro; Antonarakis, Emmanuel S (2018) PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. Expert Rev Clin Pharmacol 11:475-486
Schoch, Laura K; Cooke, Kenneth R; Wagner-Johnston, Nina D et al. (2018) Immune checkpoint inhibitors as a bridge to allogeneic transplantation with posttransplant cyclophosphamide. Blood Adv 2:2226-2229
Cuviello, Andrea; Goyal, Anshit; Zick, Aviad et al. (2018) Sporadic Malignant Glomus Tumor of the Brachial Plexus With Response to Targeted Therapy Directed Against Oncogenic BRAF. JCO Precis Oncol 2018:
Giraldo, Nicolas A; Nguyen, Peter; Engle, Elizabeth L et al. (2018) Multidimensional, quantitative assessment of PD-1/PD-L1 expression in patients with Merkel cell carcinoma and association with response to pembrolizumab. J Immunother Cancer 6:99
Barberi, Theresa; Martin, Allison; Suresh, Rahul et al. (2018) Absence of host NF-?B p50 induces murine glioblastoma tumor regression, increases survival, and decreases T-cell induction of tumor-associated macrophage M2 polarization. Cancer Immunol Immunother 67:1491-1503
Taube, Janis M; Galon, Jérôme; Sholl, Lynette M et al. (2018) Implications of the tumor immune microenvironment for staging and therapeutics. Mod Pathol 31:214-234
Krueger, Timothy E G; Thorek, Daniel L J; Denmeade, Samuel R et al. (2018) Concise Review: Mesenchymal Stem Cell-Based Drug Delivery: The Good, the Bad, the Ugly, and the Promise. Stem Cells Transl Med 7:651-663

Showing the most recent 10 out of 2393 publications